National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.
Top-decile sponsor footprint
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
490 total, page 9 of 10
Biofeedback for Fecal Incontinence
NCT00124904
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
NCT00006185
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
NCT00001860
Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis
NCT00004993
Saw Palmetto Extract in Benign Prostatic Hyperplasia
NCT00037154
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
NCT00001858
Screening for Patients Needing Kidney, Kidney-Pancreas, or Islet-Cell Transplant
NCT00001859
PTHrP and Osteoporosis
NCT00021827
Live Donors for Kidney Transplants
NCT00001856
Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation
NCT00001857
Long-Term Therapy With Ribavirin for Chronic Hepatitis C
NCT00001854
Treatment of Non-Cardiac Chest Pain With Imipramine or Cognitive-Behavioral Therapy
NCT00005575
Combination Iron Chelation Therapy
NCT00004982
Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
NCT00004466
AIDS Wasting in Women: Anabolic Effects of Testosterone
NCT00006158
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
NCT00004467
Preventing Depression Recurrence in Diabetes
NCT00374426
Treatment of Bulimia Nervosa in a Primary Care Setting
NCT00009178
Nutrition Intervention in AIDS Wasting
NCT00006167
Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
NCT00001730
Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy
NCT00004448
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
NCT00212225
Combination Drug Therapy for Patients With Hepatitis C
NCT00001729
Computer-assisted Diabetes Self-management Interventions
NCT00006163
Studies of States With Resistance to Vitamin D and Parathyroid Hormone
NCT00001242
Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome
NCT00004465
Human Sperm Binding to Transgenic Mouse Eggs
NCT00340587
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
NCT00004842
North American Study for the Treatment of Refractory Ascites (NASTRA)
NCT00006166
The Body's Affect on Vitamin C
NCT00001309
Decompression Intervention of Variceal Rebleeding Trial (DIVERT)
NCT00006161
Insulin Secretory Defects in Pima Indians at High Risk for NIDDM
NCT00410800
Treatment of Functional Bowel Disorders
NCT00006157
Diabetes Prevention Program
NCT00004992
Behavioral Treatment of Weight Gain in CF
NCT00006169
Pathogenesis of Glomerulosclerosis
NCT00001392
Genetic Markers for Focal Segmental Glomerulosclerosis
NCT00001393
Medical Therapy of Prostatic Symptoms
NCT00021814
Lamivudine for Chronic Hepatitis B
NCT00001457
Renoprotection in Early Diabetic Nephropathy in Pima Indians
NCT00340678
Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis
NCT00004316
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
NCT00004285
Lifestyle Interventions to Reduce Diabetes Risk
NCT00006162
Delaying the Progression of Diabetic Nephropathy in Pima Indians
NCT00353600
Using X-Ray Dye to Locate Hidden Parathyroid Tumors
NCT00001394
Family-Centered Diabetes Project
NCT00006159
The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)
NCT00004984
Ursodiol-Methotrexate for Primary Biliary Cirrhosis
NCT00006168
Studies of Elevated Parathyroid Activity
NCT00001277
Studies of Inherited Diseases of Metabolism
NCT00001345
What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline
50 recruiting of 490 indexed (10% open); 398 completed (81%).
Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).
Top condition: Obesity (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide
Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 490 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Mirati Therapeutics · 10% recruiting · 49 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page
490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.
- 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.